Quidel Co. (NASDAQ:QDEL) fell 0% on Thursday . The company traded as low as $42.74 and last traded at $43.72. 1,044,387 shares were traded during trading, an increase of 214% from the average session volume of 332,291 shares. The stock had previously closed at $43.72.
A number of research firms recently weighed in on QDEL. Piper Jaffray Companies reissued a “buy” rating and set a $50.00 price target on shares of Quidel in a research note on Friday, November 3rd. Canaccord Genuity reissued a “buy” rating and set a $48.00 price target on shares of Quidel in a research note on Wednesday, October 25th. Zacks Investment Research downgraded shares of Quidel from a “hold” rating to a “strong sell” rating in a research note on Tuesday, December 12th. Barclays boosted their price target on shares of Quidel from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Monday, January 22nd. Finally, BidaskClub raised shares of Quidel from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Quidel currently has an average rating of “Buy” and an average price target of $53.50.
The firm has a market capitalization of $1,490.00, a price-to-earnings ratio of -273.25, a PEG ratio of 1.49 and a beta of 1.02. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.68 and a current ratio of 6.28.
In related news, CEO Douglas C. Bryant sold 12,000 shares of the company’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $36.72, for a total transaction of $440,640.00. Following the transaction, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at approximately $10,887,222.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Douglas C. Bryant sold 36,000 shares of the company’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $37.36, for a total value of $1,344,960.00. Following the transaction, the chief executive officer now directly owns 296,493 shares in the company, valued at $11,076,978.48. The disclosure for this sale can be found here. Insiders have sold a total of 370,260 shares of company stock worth $15,293,980 over the last ninety days. 22.00% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in QDEL. Cornerstone Capital Management Holdings LLC. acquired a new position in Quidel during the 4th quarter valued at about $156,000. Great West Life Assurance Co. Can grew its stake in Quidel by 162.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,642 shares of the company’s stock valued at $204,000 after purchasing an additional 2,875 shares during the last quarter. Jane Street Group LLC purchased a new stake in Quidel during the 3rd quarter valued at about $205,000. Voya Investment Management LLC grew its stake in Quidel by 11.1% during the 2nd quarter. Voya Investment Management LLC now owns 13,636 shares of the company’s stock valued at $370,000 after purchasing an additional 1,366 shares during the last quarter. Finally, Wolverine Trading LLC purchased a new stake in Quidel during the 3rd quarter valued at about $406,000. 92.07% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Quidel (QDEL) Trading Down 0%” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://stocknewstimes.com/2018/02/22/quidel-qdel-trading-down-0.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.